Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment.

Published byRodger French Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment."— Presentation transcript:

1 Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment
Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine serum levels of interleukin (IL)–6 (A.a), tumor necrosis factor (TNF)–α (A.b), IL-1β (A.c), interferon (IFN)–γ (A.d), and IL-10 (A.e) during alemtuzumab infusion cycle are presented. Cytokine levels in cultured cell supernatants: IFN-γ (B.a), IL-17A (B.b), IL-2 (B.c), TNF-α (B.d), and IL-10 (B.e) after ex vivo Cytostim stimulation and IL-6 (C.a), TNF-α (C.b), IL-1β (C.c), and IL-10 (C.d) after ex vivo LPS stimulation are depicted. Analysis was performed before infusions started (A), after methylprednisolone (B), and after alemtuzumab (C) each of the 5 infusion days (day 1–day 5 [D1–D5]). Arrowhead indicates administration of methylprednisolone, arrow indicates administration of alemtuzumab. Mean values ± SEM are presented. Asterisks indicate a statistically significant difference (*p < 0.05, **p < 0.01, ***p < 0.001). Katja Thomas et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e228 © 2016 American Academy of Neurology

Download ppt "Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment."

Similar presentations

Geometry: Plane Figures Chapter. point A point marks a location. A A B B line segment the part of the line between 2 points endpoints.

Geometry: Plane Figures Chapter. point A point marks a location. A A B B line segment the part of the line between 2 points endpoints.
Figure 4. Inhibition of LPS-induced IL-1β and TNFα, but not IL-6, after exercise. Depicted are LPS-induced IL-1β (upper panel), IL-6 (middle panel), and.

Figure 4. Inhibition of LPS-induced IL-1β and TNFα, but not IL-6, after exercise. Depicted are LPS-induced IL-1β (upper panel), IL-6 (middle panel), and.
Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.
Figure 2 Systemic immune responses to cryptococcal antigen

Figure 2 Systemic immune responses to cryptococcal antigen
Figure 2 Evolution of MRI abnormalities in faciobrachial dystonic seizures Axial fluid- attenuated inversion recovery (FLAIR)-weighted images from patient.

Figure 2 Evolution of MRI abnormalities in faciobrachial dystonic seizures Axial fluid- attenuated inversion recovery (FLAIR)-weighted images from patient.
Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.

Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Figure 4 Expression of type 1 IFN cytokines in different aDM subtypes

Figure 4 Expression of type 1 IFN cytokines in different aDM subtypes
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.

Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.
Figure 3 Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production Decreased AHI1 in human CD4+ T cells.

Figure 3 Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production Decreased AHI1 in human CD4+ T cells.
Figure 1 MRI head in faciobrachial dystonic seizures (A) Axial fluid-attenuated inversion recovery image from patient 3 in table 2 shows T2-weighted hyperintensity.

Figure 1 MRI head in faciobrachial dystonic seizures (A) Axial fluid-attenuated inversion recovery image from patient 3 in table 2 shows T2-weighted hyperintensity.
Figure 2 The frequency of helper T cells (Th) within CD4+ population and TCRγδ within CD3+ cells is affected by FTY and DMF treatment The frequency of.

Figure 2 The frequency of helper T cells (Th) within CD4+ population and TCRγδ within CD3+ cells is affected by FTY and DMF treatment The frequency of.
Figure 3 Routine blood analysis during alemtuzumab infusion cycle

Figure 3 Routine blood analysis during alemtuzumab infusion cycle
Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.
Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.

Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.
Altered cytokine production by Klrk1−/− NOD CTL

Altered cytokine production by Klrk1−/− NOD CTL
Figure 1 Cytokine titers determined by the multiplex bead assay Plotted are cytokine titers (pg/mL) in CSF of patients with other noninflammatory neurologic.

Figure 1 Cytokine titers determined by the multiplex bead assay Plotted are cytokine titers (pg/mL) in CSF of patients with other noninflammatory neurologic.
Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)
Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.

Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.

Similar presentations

Ads by Google